Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 34 | 2021 | 2889 | 5.770 |
Why?
|
Medical Oncology | 19 | 2022 | 357 | 5.540 |
Why?
|
Colorectal Neoplasms | 31 | 2023 | 924 | 4.770 |
Why?
|
Healthcare Disparities | 11 | 2019 | 369 | 3.080 |
Why?
|
Colonic Neoplasms | 14 | 2022 | 554 | 2.360 |
Why?
|
Drug Costs | 5 | 2020 | 62 | 2.140 |
Why?
|
Patient Care Bundles | 3 | 2018 | 19 | 1.830 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 26 | 2023 | 2434 | 1.810 |
Why?
|
Health Care Costs | 5 | 2019 | 237 | 1.680 |
Why?
|
Health Care Reform | 5 | 2015 | 90 | 1.580 |
Why?
|
Spiritual Therapies | 2 | 2021 | 4 | 1.580 |
Why?
|
Adenocarcinoma | 15 | 2024 | 1160 | 1.550 |
Why?
|
Health Equity | 2 | 2023 | 75 | 1.530 |
Why?
|
United States | 35 | 2022 | 6637 | 1.440 |
Why?
|
Rectal Neoplasms | 8 | 2024 | 114 | 1.420 |
Why?
|
Antineoplastic Agents | 12 | 2021 | 2351 | 1.410 |
Why?
|
National Cancer Institute (U.S.) | 3 | 2017 | 70 | 1.370 |
Why?
|
Peritoneal Neoplasms | 7 | 2023 | 175 | 1.310 |
Why?
|
Medicare | 9 | 2022 | 404 | 1.310 |
Why?
|
Appendiceal Neoplasms | 6 | 2023 | 26 | 1.280 |
Why?
|
Humans | 116 | 2024 | 86281 | 1.270 |
Why?
|
Hyperthermia, Induced | 6 | 2023 | 71 | 1.250 |
Why?
|
Delivery of Health Care | 6 | 2021 | 423 | 1.240 |
Why?
|
Advance Care Planning | 2 | 2018 | 43 | 1.210 |
Why?
|
Minority Groups | 4 | 2017 | 132 | 1.180 |
Why?
|
Religion | 2 | 2018 | 87 | 1.160 |
Why?
|
Reimbursement Mechanisms | 6 | 2019 | 40 | 1.150 |
Why?
|
Health Literacy | 2 | 2019 | 70 | 1.130 |
Why?
|
Clinical Trials as Topic | 6 | 2019 | 1168 | 1.130 |
Why?
|
Societies, Medical | 4 | 2018 | 572 | 1.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2020 | 508 | 1.050 |
Why?
|
Patient Education as Topic | 2 | 2019 | 351 | 1.030 |
Why?
|
Patient Participation | 3 | 2022 | 216 | 0.900 |
Why?
|
Survival Analysis | 5 | 2020 | 1536 | 0.860 |
Why?
|
Terminal Care | 2 | 2021 | 130 | 0.830 |
Why?
|
Models, Economic | 3 | 2019 | 60 | 0.810 |
Why?
|
Middle Aged | 49 | 2024 | 24957 | 0.790 |
Why?
|
Hockey | 1 | 2021 | 9 | 0.790 |
Why?
|
American Cancer Society | 2 | 2017 | 13 | 0.780 |
Why?
|
Stomach Neoplasms | 6 | 2021 | 266 | 0.770 |
Why?
|
Insurance, Health, Reimbursement | 3 | 2016 | 59 | 0.760 |
Why?
|
Aged | 47 | 2022 | 18353 | 0.730 |
Why?
|
Male | 55 | 2024 | 40860 | 0.710 |
Why?
|
Urban Population | 2 | 2018 | 213 | 0.710 |
Why?
|
Breast Neoplasms | 8 | 2022 | 2881 | 0.710 |
Why?
|
Health Expenditures | 2 | 2018 | 86 | 0.700 |
Why?
|
Racism | 1 | 2021 | 81 | 0.700 |
Why?
|
Periodicals as Topic | 2 | 2019 | 167 | 0.700 |
Why?
|
Multimedia | 1 | 2019 | 9 | 0.700 |
Why?
|
Insurance, Health | 2 | 2021 | 158 | 0.700 |
Why?
|
Prognosis | 11 | 2023 | 3669 | 0.690 |
Why?
|
Female | 58 | 2023 | 44405 | 0.690 |
Why?
|
Social Justice | 1 | 2019 | 49 | 0.670 |
Why?
|
Medicaid | 3 | 2017 | 216 | 0.640 |
Why?
|
Health Personnel | 1 | 2020 | 202 | 0.630 |
Why?
|
Organizational Objectives | 1 | 2017 | 27 | 0.630 |
Why?
|
Social Class | 3 | 2021 | 127 | 0.620 |
Why?
|
Patient Care Team | 1 | 2020 | 280 | 0.620 |
Why?
|
Health Status Disparities | 3 | 2020 | 170 | 0.610 |
Why?
|
Glucuronosyltransferase | 4 | 2020 | 184 | 0.610 |
Why?
|
Patient Protection and Affordable Care Act | 2 | 2017 | 66 | 0.600 |
Why?
|
Metformin | 2 | 2018 | 128 | 0.590 |
Why?
|
Guidelines as Topic | 1 | 2018 | 162 | 0.590 |
Why?
|
Angiogenesis Inhibitors | 4 | 2017 | 309 | 0.590 |
Why?
|
Health Services Misuse | 1 | 2016 | 19 | 0.580 |
Why?
|
Health Services Research | 1 | 2017 | 135 | 0.580 |
Why?
|
Quality of Health Care | 3 | 2017 | 380 | 0.580 |
Why?
|
Biomedical Research | 2 | 2017 | 375 | 0.570 |
Why?
|
Fluorouracil | 14 | 2022 | 556 | 0.570 |
Why?
|
Health Policy | 2 | 2014 | 180 | 0.560 |
Why?
|
Internal-External Control | 1 | 2016 | 44 | 0.560 |
Why?
|
Critical Pathways | 1 | 2016 | 35 | 0.550 |
Why?
|
Bevacizumab | 8 | 2022 | 281 | 0.540 |
Why?
|
Mortality, Premature | 1 | 2015 | 4 | 0.530 |
Why?
|
Precision Medicine | 3 | 2018 | 394 | 0.530 |
Why?
|
Physicians | 2 | 2020 | 672 | 0.510 |
Why?
|
Neoplasm Staging | 14 | 2023 | 1932 | 0.510 |
Why?
|
Survival Rate | 12 | 2023 | 1856 | 0.500 |
Why?
|
Chemoprevention | 1 | 2014 | 91 | 0.490 |
Why?
|
Aged, 80 and over | 22 | 2021 | 6481 | 0.480 |
Why?
|
Heart Arrest | 1 | 2017 | 264 | 0.480 |
Why?
|
Ambulatory Care | 1 | 2015 | 180 | 0.460 |
Why?
|
Antibodies, Monoclonal, Humanized | 5 | 2020 | 929 | 0.460 |
Why?
|
Intensive Care Units | 1 | 2016 | 373 | 0.460 |
Why?
|
Health Services Accessibility | 5 | 2020 | 392 | 0.430 |
Why?
|
Hospitalization | 2 | 2016 | 844 | 0.430 |
Why?
|
Mass Screening | 7 | 2021 | 615 | 0.420 |
Why?
|
Cytoreduction Surgical Procedures | 8 | 2023 | 71 | 0.420 |
Why?
|
Palliative Care | 3 | 2023 | 256 | 0.420 |
Why?
|
Hypoglycemic Agents | 1 | 2014 | 377 | 0.410 |
Why?
|
Socioeconomic Factors | 6 | 2020 | 567 | 0.410 |
Why?
|
Treatment Outcome | 22 | 2023 | 7949 | 0.410 |
Why?
|
Patient Care | 1 | 2012 | 100 | 0.400 |
Why?
|
Early Detection of Cancer | 5 | 2021 | 387 | 0.390 |
Why?
|
Leucovorin | 10 | 2022 | 218 | 0.390 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 378 | 0.370 |
Why?
|
Neuroendocrine Tumors | 2 | 2023 | 105 | 0.370 |
Why?
|
Spirituality | 2 | 2021 | 87 | 0.360 |
Why?
|
Algorithms | 1 | 2018 | 1828 | 0.360 |
Why?
|
Camptothecin | 5 | 2022 | 189 | 0.360 |
Why?
|
Retrospective Studies | 16 | 2023 | 8431 | 0.350 |
Why?
|
Liver Neoplasms | 4 | 2023 | 731 | 0.350 |
Why?
|
Adult | 28 | 2023 | 25577 | 0.350 |
Why?
|
Costs and Cost Analysis | 3 | 2022 | 153 | 0.340 |
Why?
|
Receptors, Progesterone | 1 | 2010 | 165 | 0.340 |
Why?
|
Surveys and Questionnaires | 6 | 2020 | 2495 | 0.340 |
Why?
|
Antibodies, Monoclonal | 5 | 2021 | 1376 | 0.330 |
Why?
|
SEER Program | 2 | 2006 | 181 | 0.330 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2019 | 106 | 0.330 |
Why?
|
Prospective Studies | 10 | 2022 | 4194 | 0.330 |
Why?
|
Esophageal Neoplasms | 3 | 2020 | 320 | 0.330 |
Why?
|
Receptor, ErbB-2 | 1 | 2010 | 223 | 0.320 |
Why?
|
Receptors, Estrogen | 1 | 2010 | 382 | 0.320 |
Why?
|
Income | 2 | 2019 | 75 | 0.310 |
Why?
|
Follow-Up Studies | 6 | 2019 | 3616 | 0.310 |
Why?
|
Combined Modality Therapy | 8 | 2023 | 1680 | 0.310 |
Why?
|
Disease-Free Survival | 9 | 2022 | 1203 | 0.300 |
Why?
|
Decision Making | 3 | 2018 | 641 | 0.300 |
Why?
|
Government Regulation | 2 | 2019 | 49 | 0.290 |
Why?
|
Diabetes Mellitus | 1 | 2014 | 801 | 0.290 |
Why?
|
Forecasting | 2 | 2017 | 303 | 0.280 |
Why?
|
Incidence | 4 | 2017 | 1568 | 0.280 |
Why?
|
Organoplatinum Compounds | 6 | 2018 | 94 | 0.280 |
Why?
|
Clinical Decision-Making | 3 | 2018 | 255 | 0.270 |
Why?
|
Thromboembolism | 1 | 2006 | 119 | 0.260 |
Why?
|
Case-Control Studies | 4 | 2017 | 1801 | 0.260 |
Why?
|
Pancreatic Neoplasms | 3 | 2020 | 645 | 0.260 |
Why?
|
Neoadjuvant Therapy | 4 | 2024 | 315 | 0.260 |
Why?
|
Decision Support Techniques | 2 | 2016 | 160 | 0.250 |
Why?
|
Cohort Studies | 9 | 2023 | 2759 | 0.250 |
Why?
|
Risk Factors | 7 | 2017 | 5397 | 0.250 |
Why?
|
Capecitabine | 3 | 2022 | 95 | 0.250 |
Why?
|
Chicago | 5 | 2020 | 1377 | 0.240 |
Why?
|
Pharmacogenetics | 2 | 2018 | 434 | 0.240 |
Why?
|
Surgical Oncology | 1 | 2023 | 27 | 0.230 |
Why?
|
Databases, Factual | 3 | 2019 | 808 | 0.230 |
Why?
|
Venous Thrombosis | 1 | 2006 | 242 | 0.230 |
Why?
|
Appendix | 1 | 2023 | 31 | 0.220 |
Why?
|
Circulating Tumor DNA | 1 | 2023 | 37 | 0.220 |
Why?
|
Neoplasms, Second Primary | 2 | 2024 | 252 | 0.210 |
Why?
|
Neoplasm Metastasis | 5 | 2019 | 1056 | 0.210 |
Why?
|
Kaplan-Meier Estimate | 5 | 2021 | 859 | 0.210 |
Why?
|
Carcinoma, Renal Cell | 1 | 2006 | 425 | 0.200 |
Why?
|
Cost-Benefit Analysis | 4 | 2019 | 450 | 0.200 |
Why?
|
Qualitative Research | 2 | 2020 | 256 | 0.200 |
Why?
|
Cetuximab | 3 | 2017 | 113 | 0.200 |
Why?
|
Catheter Ablation | 1 | 2023 | 233 | 0.200 |
Why?
|
Food Quality | 1 | 2020 | 1 | 0.200 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 857 | 0.200 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2020 | 21 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2023 | 1305 | 0.190 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2020 | 22 | 0.190 |
Why?
|
Adiponectin | 1 | 2020 | 24 | 0.190 |
Why?
|
ras Proteins | 2 | 2011 | 128 | 0.190 |
Why?
|
Death | 1 | 2021 | 72 | 0.190 |
Why?
|
Biomarkers, Tumor | 3 | 2018 | 1461 | 0.190 |
Why?
|
Octreotide | 1 | 2020 | 16 | 0.190 |
Why?
|
Coordination Complexes | 1 | 2020 | 19 | 0.190 |
Why?
|
Kidney Neoplasms | 1 | 2006 | 620 | 0.190 |
Why?
|
Molecular Targeted Therapy | 2 | 2020 | 266 | 0.190 |
Why?
|
Pharmacists | 1 | 2020 | 32 | 0.180 |
Why?
|
Metastasectomy | 1 | 2019 | 9 | 0.180 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2020 | 114 | 0.180 |
Why?
|
Intestinal Neoplasms | 1 | 2020 | 56 | 0.180 |
Why?
|
Adaptation, Psychological | 1 | 2020 | 157 | 0.180 |
Why?
|
Nigeria | 1 | 2020 | 152 | 0.180 |
Why?
|
Drug Prescriptions | 2 | 2018 | 141 | 0.180 |
Why?
|
Patient Acceptance of Health Care | 2 | 2020 | 237 | 0.170 |
Why?
|
Patient-Centered Care | 1 | 2021 | 202 | 0.170 |
Why?
|
Practice Patterns, Physicians' | 3 | 2013 | 578 | 0.170 |
Why?
|
Self Efficacy | 1 | 2019 | 53 | 0.170 |
Why?
|
Organ Preservation | 3 | 2024 | 81 | 0.170 |
Why?
|
Cancer Care Facilities | 1 | 2018 | 28 | 0.170 |
Why?
|
Multiple Myeloma | 1 | 2022 | 307 | 0.170 |
Why?
|
Drug Administration Schedule | 5 | 2020 | 916 | 0.160 |
Why?
|
Chemoradiotherapy, Adjuvant | 2 | 2015 | 35 | 0.160 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2020 | 185 | 0.160 |
Why?
|
Leukemia | 1 | 2020 | 318 | 0.160 |
Why?
|
Hematology | 1 | 2018 | 29 | 0.160 |
Why?
|
Lung Neoplasms | 3 | 2022 | 2260 | 0.160 |
Why?
|
Intestinal Obstruction | 1 | 2018 | 88 | 0.160 |
Why?
|
Residence Characteristics | 1 | 2019 | 195 | 0.160 |
Why?
|
Radiosurgery | 1 | 2021 | 272 | 0.160 |
Why?
|
Salvage Therapy | 2 | 2017 | 232 | 0.160 |
Why?
|
Proto-Oncogene Proteins | 2 | 2011 | 645 | 0.160 |
Why?
|
Delayed Diagnosis | 1 | 2017 | 29 | 0.160 |
Why?
|
Rectum | 1 | 2018 | 146 | 0.160 |
Why?
|
Quality of Life | 3 | 2021 | 1575 | 0.160 |
Why?
|
Medical Order Entry Systems | 1 | 2017 | 25 | 0.150 |
Why?
|
Cost Savings | 2 | 2014 | 66 | 0.150 |
Why?
|
Sirolimus | 1 | 2018 | 169 | 0.150 |
Why?
|
Anus Neoplasms | 1 | 2017 | 30 | 0.150 |
Why?
|
Attitude to Health | 1 | 2018 | 220 | 0.140 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2017 | 108 | 0.140 |
Why?
|
Decision Support Systems, Clinical | 1 | 2017 | 103 | 0.140 |
Why?
|
Dihydrouracil Dehydrogenase (NADP) | 1 | 2016 | 29 | 0.140 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 141 | 0.140 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2019 | 850 | 0.140 |
Why?
|
Exercise | 1 | 2019 | 315 | 0.140 |
Why?
|
Pyrimidines | 2 | 2011 | 370 | 0.140 |
Why?
|
Age Factors | 3 | 2019 | 1842 | 0.140 |
Why?
|
Drug Therapy | 1 | 2016 | 70 | 0.140 |
Why?
|
Polymorphism, Genetic | 1 | 2019 | 819 | 0.130 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2017 | 589 | 0.130 |
Why?
|
Educational Status | 1 | 2016 | 187 | 0.130 |
Why?
|
Physician's Role | 1 | 2017 | 179 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 81 | 0.130 |
Why?
|
Collagen Type I | 1 | 2015 | 62 | 0.130 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 826 | 0.130 |
Why?
|
Episode of Care | 1 | 2014 | 7 | 0.130 |
Why?
|
Chemoradiotherapy | 3 | 2023 | 301 | 0.130 |
Why?
|
Choice Behavior | 1 | 2016 | 160 | 0.130 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2017 | 189 | 0.130 |
Why?
|
Commerce | 1 | 2014 | 29 | 0.130 |
Why?
|
Politics | 1 | 2015 | 50 | 0.130 |
Why?
|
Colon | 1 | 2018 | 495 | 0.130 |
Why?
|
Specialization | 1 | 2015 | 65 | 0.130 |
Why?
|
Genetic Testing | 2 | 2018 | 535 | 0.120 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2016 | 236 | 0.120 |
Why?
|
Social Support | 1 | 2016 | 193 | 0.120 |
Why?
|
Health Insurance Exchanges | 1 | 2014 | 2 | 0.120 |
Why?
|
Logistic Models | 3 | 2019 | 1184 | 0.120 |
Why?
|
Primary Prevention | 1 | 2014 | 85 | 0.120 |
Why?
|
Eligibility Determination | 1 | 2014 | 31 | 0.120 |
Why?
|
Research Design | 1 | 2017 | 594 | 0.120 |
Why?
|
Time Factors | 5 | 2019 | 5198 | 0.120 |
Why?
|
Policy Making | 1 | 2014 | 62 | 0.120 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2011 | 153 | 0.120 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 1030 | 0.120 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 2 | 2023 | 15 | 0.120 |
Why?
|
Delaware | 1 | 2013 | 2 | 0.110 |
Why?
|
Infusions, Intravenous | 3 | 2020 | 429 | 0.110 |
Why?
|
Neovascularization, Pathologic | 1 | 2015 | 352 | 0.110 |
Why?
|
Comorbidity | 2 | 2022 | 943 | 0.110 |
Why?
|
New York | 1 | 2013 | 69 | 0.110 |
Why?
|
Off-Label Use | 1 | 2012 | 16 | 0.110 |
Why?
|
Patient Outcome Assessment | 1 | 2013 | 83 | 0.110 |
Why?
|
Insurance Coverage | 1 | 2014 | 115 | 0.110 |
Why?
|
Maximum Tolerated Dose | 3 | 2019 | 270 | 0.110 |
Why?
|
Carcinoembryonic Antigen | 2 | 2023 | 41 | 0.110 |
Why?
|
Paclitaxel | 2 | 2019 | 460 | 0.110 |
Why?
|
Patents as Topic | 1 | 2012 | 12 | 0.110 |
Why?
|
Geriatric Assessment | 1 | 2013 | 166 | 0.110 |
Why?
|
Genomics | 1 | 2017 | 710 | 0.100 |
Why?
|
Attitude of Health Personnel | 2 | 2016 | 636 | 0.100 |
Why?
|
Life Style | 1 | 2013 | 188 | 0.100 |
Why?
|
Peptides | 1 | 2015 | 639 | 0.100 |
Why?
|
Alanine | 1 | 2012 | 85 | 0.100 |
Why?
|
Triazines | 1 | 2012 | 47 | 0.100 |
Why?
|
Young Adult | 4 | 2018 | 5961 | 0.100 |
Why?
|
Chromosomal Instability | 1 | 2011 | 19 | 0.100 |
Why?
|
Cost Sharing | 1 | 2011 | 14 | 0.100 |
Why?
|
Ploidies | 1 | 2011 | 40 | 0.100 |
Why?
|
Mutation | 3 | 2023 | 3952 | 0.100 |
Why?
|
Longitudinal Studies | 1 | 2014 | 1015 | 0.100 |
Why?
|
Loss of Heterozygosity | 1 | 2011 | 85 | 0.100 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2011 | 70 | 0.100 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2011 | 137 | 0.100 |
Why?
|
Thiazoles | 1 | 2011 | 131 | 0.090 |
Why?
|
Vitamin D | 1 | 2013 | 261 | 0.090 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2017 | 1075 | 0.090 |
Why?
|
Pilot Projects | 3 | 2018 | 837 | 0.090 |
Why?
|
Statistics as Topic | 1 | 2010 | 237 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2018 | 468 | 0.090 |
Why?
|
Multivariate Analysis | 3 | 2020 | 997 | 0.090 |
Why?
|
Genotype | 3 | 2020 | 1850 | 0.090 |
Why?
|
Disease Progression | 3 | 2019 | 1531 | 0.090 |
Why?
|
Drug Therapy, Combination | 1 | 2011 | 893 | 0.090 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 2 | 2020 | 56 | 0.080 |
Why?
|
Multicenter Studies as Topic | 1 | 2008 | 156 | 0.080 |
Why?
|
Positron-Emission Tomography | 2 | 2020 | 329 | 0.080 |
Why?
|
ErbB Receptors | 1 | 2011 | 485 | 0.080 |
Why?
|
Prostatic Neoplasms | 1 | 2019 | 1708 | 0.080 |
Why?
|
Treatment Failure | 1 | 2008 | 284 | 0.080 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2012 | 380 | 0.080 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 2350 | 0.080 |
Why?
|
Body Mass Index | 2 | 2009 | 770 | 0.070 |
Why?
|
Predictive Value of Tests | 3 | 2016 | 1671 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 1 | 2011 | 589 | 0.070 |
Why?
|
Sex Factors | 2 | 2021 | 1053 | 0.070 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2008 | 276 | 0.070 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2006 | 67 | 0.070 |
Why?
|
Administration, Oral | 2 | 2022 | 683 | 0.070 |
Why?
|
Canada | 2 | 2017 | 204 | 0.070 |
Why?
|
Imatinib Mesylate | 1 | 2006 | 126 | 0.070 |
Why?
|
Patient Safety | 2 | 2019 | 212 | 0.070 |
Why?
|
Health Care Surveys | 2 | 2020 | 277 | 0.070 |
Why?
|
Interferon-alpha | 1 | 2006 | 233 | 0.070 |
Why?
|
Benzamides | 1 | 2006 | 226 | 0.070 |
Why?
|
Culture | 1 | 2005 | 53 | 0.060 |
Why?
|
Age Distribution | 1 | 2005 | 204 | 0.060 |
Why?
|
Regression Analysis | 1 | 2006 | 595 | 0.060 |
Why?
|
Piperazines | 1 | 2006 | 272 | 0.060 |
Why?
|
Patient Selection | 2 | 2018 | 685 | 0.060 |
Why?
|
Microwaves | 1 | 2023 | 34 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 1958 | 0.060 |
Why?
|
Advance Directives | 1 | 2023 | 64 | 0.060 |
Why?
|
Peritoneum | 1 | 2023 | 57 | 0.060 |
Why?
|
Risk Assessment | 3 | 2019 | 2253 | 0.060 |
Why?
|
Hepatectomy | 1 | 2023 | 166 | 0.050 |
Why?
|
Monoterpenes | 1 | 2022 | 5 | 0.050 |
Why?
|
Head and Neck Neoplasms | 1 | 2009 | 1051 | 0.050 |
Why?
|
GPI-Linked Proteins | 1 | 2022 | 50 | 0.050 |
Why?
|
Celecoxib | 1 | 2022 | 31 | 0.050 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2023 | 262 | 0.050 |
Why?
|
Dietary Fats | 1 | 2022 | 134 | 0.050 |
Why?
|
Occult Blood | 1 | 2021 | 16 | 0.050 |
Why?
|
Physician-Patient Relations | 2 | 2020 | 610 | 0.050 |
Why?
|
Drug Combinations | 1 | 2022 | 222 | 0.050 |
Why?
|
Cause of Death | 1 | 2022 | 277 | 0.050 |
Why?
|
Gastrectomy | 1 | 2021 | 68 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2023 | 380 | 0.050 |
Why?
|
C-Peptide | 1 | 2020 | 174 | 0.050 |
Why?
|
Illinois | 1 | 2021 | 461 | 0.050 |
Why?
|
Confidence Intervals | 1 | 2020 | 228 | 0.050 |
Why?
|
Obesity | 1 | 2006 | 962 | 0.050 |
Why?
|
Odds Ratio | 2 | 2015 | 677 | 0.040 |
Why?
|
Organometallic Compounds | 1 | 2020 | 132 | 0.040 |
Why?
|
Chronic Disease | 1 | 2023 | 968 | 0.040 |
Why?
|
Colonoscopy | 1 | 2021 | 260 | 0.040 |
Why?
|
Diet | 1 | 2022 | 442 | 0.040 |
Why?
|
Albumins | 1 | 2019 | 133 | 0.040 |
Why?
|
Non-Randomized Controlled Trials as Topic | 1 | 2018 | 6 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 169 | 0.040 |
Why?
|
Biliary Tract Neoplasms | 1 | 2019 | 33 | 0.040 |
Why?
|
Telemedicine | 1 | 2021 | 168 | 0.040 |
Why?
|
Maintenance Chemotherapy | 1 | 2019 | 76 | 0.040 |
Why?
|
Markov Chains | 1 | 2019 | 125 | 0.040 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 44 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 1 | 2019 | 138 | 0.040 |
Why?
|
Filgrastim | 1 | 2017 | 56 | 0.040 |
Why?
|
Genotyping Techniques | 1 | 2018 | 68 | 0.040 |
Why?
|
Drug Synergism | 1 | 2018 | 303 | 0.040 |
Why?
|
Drug Labeling | 1 | 2017 | 41 | 0.040 |
Why?
|
Leukocytes, Mononuclear | 1 | 2018 | 196 | 0.040 |
Why?
|
Genes, ras | 1 | 2017 | 96 | 0.040 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2018 | 182 | 0.040 |
Why?
|
Hospitals | 1 | 2019 | 290 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 2020 | 532 | 0.040 |
Why?
|
Neoplasm Invasiveness | 1 | 2018 | 551 | 0.040 |
Why?
|
Postoperative Care | 1 | 2017 | 220 | 0.040 |
Why?
|
Stakeholder Participation | 1 | 2016 | 19 | 0.040 |
Why?
|
Academic Medical Centers | 1 | 2019 | 377 | 0.030 |
Why?
|
Advisory Committees | 1 | 2016 | 90 | 0.030 |
Why?
|
Snake Venoms | 1 | 2015 | 10 | 0.030 |
Why?
|
Phosphorylation | 1 | 2018 | 1101 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2018 | 329 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2015 | 72 | 0.030 |
Why?
|
Cost of Illness | 1 | 2016 | 150 | 0.030 |
Why?
|
Preoperative Care | 1 | 2017 | 390 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2017 | 363 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2017 | 480 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2018 | 319 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2016 | 294 | 0.030 |
Why?
|
Pyrroles | 1 | 2015 | 184 | 0.030 |
Why?
|
Preoperative Period | 1 | 2014 | 91 | 0.030 |
Why?
|
Haplotypes | 1 | 2016 | 642 | 0.030 |
Why?
|
Remission Induction | 1 | 2015 | 722 | 0.030 |
Why?
|
Indoles | 1 | 2015 | 318 | 0.030 |
Why?
|
Insurance Claim Review | 1 | 2012 | 41 | 0.030 |
Why?
|
Health Services for the Aged | 1 | 2012 | 27 | 0.030 |
Why?
|
Appetite | 1 | 2012 | 26 | 0.030 |
Why?
|
Collagen Type IV | 1 | 2012 | 24 | 0.030 |
Why?
|
alpha-Fetoproteins | 1 | 2012 | 45 | 0.030 |
Why?
|
Adolescent | 2 | 2018 | 8968 | 0.030 |
Why?
|
Microsatellite Instability | 1 | 2011 | 40 | 0.030 |
Why?
|
Self Report | 1 | 2013 | 287 | 0.030 |
Why?
|
Deoxycytidine | 1 | 2012 | 237 | 0.030 |
Why?
|
Dasatinib | 1 | 2011 | 37 | 0.030 |
Why?
|
src-Family Kinases | 1 | 2011 | 74 | 0.020 |
Why?
|
Fatigue | 1 | 2012 | 174 | 0.020 |
Why?
|
Nausea | 1 | 2012 | 175 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2011 | 526 | 0.020 |
Why?
|
Recurrence | 1 | 2010 | 1137 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2012 | 1610 | 0.020 |
Why?
|
Models, Statistical | 1 | 2010 | 574 | 0.020 |
Why?
|
Hypertension | 1 | 2012 | 1139 | 0.010 |
Why?
|
Animals | 1 | 2022 | 26518 | 0.010 |
Why?
|